Faster HIV-1 Disease Progression among Brazilian Individuals Recently Infected with CXCR4-Utilizing Strains by Araripe Sucupira, Maria Cecilia et al.
  Universidade de São Paulo
 
2012
 
Faster HIV-1 Disease Progression among
Brazilian Individuals Recently Infected with
CXCR4-Utilizing Strains
 
 
PLOS ONE, SAN FRANCISCO, v. 7, n. 1, supl. 1, Part 2, pp. 138-142, 46023, 2012
http://www.producao.usp.br/handle/BDPI/41165
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Sem comunidade WoS
Faster HIV-1 Disease Progression among Brazilian
Individuals Recently Infected with CXCR4-Utilizing
Strains
Maria Cecilia Araripe Sucupira1, Sabri Sanabani2, Rodrigo M. Cortes1, Maria Teresa M. Giret3, Helena
Tomiyama1, Mariana M. Sauer1, Ester Cerdeira Sabino4, Luiz Mario Janini5, Esper Georges Kallas3,
Ricardo Sobhie Diaz1*
1 Infectious Diseases Division, Federal University of Sao Paulo, Sao Paulo, Brazil, 2 Sao Paulo Blood Bank, Fundacao Pro-Sangue, Sao Paulo, Brazil, 3Division of Clinical
Immunology and Allergy, University of Sao Paulo, Sao Paulo, Brazil, 4 Infectious Diseases Division, University of Sao Paulo, Sao Paulo, Brazil, 5Microbiology Division,
Federal University of Sao Paulo, Sao Paulo, Brazil
Abstract
Introduction: Primary HIV infection is usually caused by R5 viruses, and there is an association between the emergence of
CCXR4-utilizing strains and faster disease progression. We characterized HIV-1 from a cohort of recently infected individuals
in Brazil, predicted the virus’s co-receptor use based on the env genotype and attempted to correlate virus profiles with
disease progression.
Methods: A total of 72 recently infected HIV patients were recruited based on the Serologic Testing Algorithm for Recent
HIV Seroconversion and were followed every three to four months for up to 78 weeks. The HIV-1 V3 region was
characterized by sequencing nine to twelve weeks after enrollment. Disease progression was characterized by CD4+ T-cell
count decline to levels consistently below 350 cells/mL.
Results: Twelve out of 72 individuals (17%) were predicted to harbor CXCR4-utilizing strains; a baseline CD4,350 was more
frequent among these individuals (p = 0.03). Fifty-seven individuals that were predicted to have CCR5-utilizing viruses and
10 individuals having CXCR4-utilizing strains presented with baseline CD4.350; after 78 weeks, 33 individuals with CCR5
strains and one individual with CXCR4 strains had CD4.350 (p = 0.001). There was no association between CD4 decline and
demographic characteristics or HIV-1 subtype.
Conclusions: Our findings confirm the presence of strains with higher in vitro pathogenicity during early HIV infection,
suggesting that even among recently infected individuals, rapid progression may be a consequence of the early emergence
of CXCR4-utilizing strains. Characterizing the HIV-1 V3 region by sequencing may be useful in predicting disease progression
and guiding treatment initiation decisions.
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Introduction
HIV-1 disease progression, as reflected by either CD4+ T cell
decline or opportunistic diseases, may be related to host and/or
virus characteristics. The observation of the natural history of
HIV-1 infection in well-characterized cohorts established before
the antiretroviral treatment era indicates that the mean time of
progression to AIDS is 10 years, although AIDS can develop in as
little as two years in a proportion of patients [1]. On the other
hand, a proportion of HIV-infected individuals, so-called elite
controllers, will not show any CD4 decline over time due to
extremely low levels of virus replication, which does not necessarily
prevent the HIV-related cell activation or an accelerated aging
process [2].
Certain host features are recognized as the main driving force
behind disease progression or virus evolution. For example, the
CCR5 allele polymorphism in individuals presenting heterozygous
deletion of 32 nucleotides (delta 32) is associated with slower
disease progression [3] and even better immunologic response to
antiretroviral treatment [4]. The same low rates of CD4+ T cell
decline are observed in individuals presenting the CCR2-64I
mutation [5] or other specific class-I and -II HLA alleles that may
have a negative or positive impact on HIV-1 disease progression
[6]. Other host-related factors associated with HIV-1 disease
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progression include a polymorphism at the SDF1-39A conserved
segment of the 39 untranslated region of the SDF-1 structural gene
transcript, which, in homozygous individuals (SDF1-39A/39A), is
associated with delayed onset of AIDS [7]. Less clear however, is
the relationship between co-infections with some other pathogens
that may either increase or decrease cell activation, although co-
infection with GBV, which is associated with decreased cell
activation [8], is more clearly associated with slower disease
progression [9] and better rates of antiretroviral response [10].
The influence of HIV-1 genetic diversity on viral evolution and
disease progression has also been recognized. Over time, there is
an association between the emergence of CXCR4 tropic viruses
and faster disease progression [11]. However, although primary
infection is caused by viruses that exclusively use the CCR5 co-
receptor, infection by dual-tropic viruses may be associated with
rapid disease progression [12]. It has been reported that HIV
evolves in a host-specific manner, and even among individuals
infected with the same viral strain, disease progression may differ,
with the emergence of CXCR4-tropic viruses being neither
homogeneous nor predictable [13]. Although controversial,
biological differences have also been demonstrated between HIV
types/subtypes. It has been documented that HIV replication,
transmission, cell activation, and disease progression are lower in
HIV-2 infection compared to HIV-1 infection [14]. Interestingly,
duplication in the NF-kB site, which has been associated with
increased pathogenesis in HIV-1 subtype C [15], was also
associated with rapid disease progression in one patient infected
with HIV-2 [16]. Furthermore, it has also been reported that
disease progression among individuals infected with subtypes D
and C is faster than in those infected with subtypes A and A/G in
Africa [17], and that subtype D infection leads to faster rates of
CD4 cell decline and subsequent virological failure compared to
infection with clade B and other non-clade B HIV strains in
England [18]. It may be conceivable as well that the genetic
diversity of the viruses may influence the pace of HIV-1 tropism
change because the emergence of X4 viruses occurs very early
among subtype D-infected individuals, and it occurs late in
infections caused by subtype C viruses [19,20],[21].
HIV epidemics in Brazil present co-circulating HIV-1 subtypes
B, F and C, and few Circulating Recombinant Forms. According to
predictions using Bayesian Markov chain Monte Carlo methods
and the Reversible-jump MCMC method, HIV-1 subtype B
emerged in 1971, subtype F emerged in 1981, BF recombinants
emerged in 1989, subtype C emerged in 1987, and BC
recombinants emerged in 1992 [22]. There is also a sub-lineage
of subtype B harboring the GWGR motif instead of the GPGR
motif at the tip of the V3 loop, which was already detectable early in
the course of the Brazilian epidemics, in 1983 [23]. Additionally,
some reports have suggested that this Brazilian strain (subtype B0)
will lead to a slower pace of disease progression than the usual North
American/European subtype B present in Brazil [24,25].
In this study, we characterized HIV-1 from a cohort of recently
infected individuals in Brazil and attempted to correlate the rate of
CD4+ T cell decline with the genetic diversity of infecting HIV
strains, including predicted co-receptor use and/or infection by
subtype B0. It has been demonstrated that the specificity of
genotype-based predictions of HIV-1 CXCR4 use is usually high
[26,27], as is the specificity of predictions of virologic response to
certain CCR5 inhibitors [28].
Results
Seventy-two individuals were initially included in the cohort.
Seventy (94.6%) were male, 90% were men who have sex with
men and none had acquired HIV through blood exposure. The
mean age was 32.7 years, ranging from 20 to 56, the mean viral
load was 72,552 (80,443) copies/mL (4.9 log10), ranging from
,400 to 703,000 copies/mL (,2.6 to 5.8 log10), and the mean
CD4+ T cell count was 573 cells/mL, ranging from 83 to 2,449
cells/mL. It is described here the analysis for the prediction of co-
receptor use using false positive rate of 10%, since it correlated
best with disease progression in this group of patients. According
to the V3 region profile, 12 out of 72 individuals (17%) were
predicted to harbor CXCR4-utilizing strains, as predicted by the
bioinformatics tool Geno2pheno[coreceptor]. According to the lab
tests results from the first visit, 5 out of the 12 patients who were
predicted to be infected with CXCR4-utilizing HIV strains and 8
out of the 60 who were predicted to be infected with CCR5-
utilizing strains presented with baseline CD4+ T cell counts lower
than 350 cells/mL (p = 0.03, Fisher’s exact test). Table 1 depicts the
demographic and virologic/immunologic characteristics of indi-
viduals infected with R5 or CXCR4-tropic viruses.
Five R5-infected individuals presented transmitted drug-resis-
tant strains, compared to one CXCR4-tropic HIV-infected
individual, for a prevalence of 8.3%. Mutations were as follows:
K103N (1 X4), D30N (1), L10I/A71T+M184V+K103N (1),
K103N/Y181C (1), M184I (1), K103n+M184V (1). As seen in
Table 1, there were no differences in the mean HIV-1 baseline
viral load, mean baseline CD4 count, age, HIV-1 subtype, gender,
route of HIV-1 transmission, and transmitted drug-resistant strains
between individuals infected by R5- or CXCR4-utilizing viruses.
As seen in Figure 1, 68 individuals were infected with subtype B,
according to the V3 sequence, two were infected with subtype F,
one with subtype C, and one with subtype A, which clustered
closer to CRF_2 sequences (data not shown). Forty-two clade B-
infected individuals harbored a proline at the tip of the V3 loop
Table 1. Characteristics of individuals infected by different
tropic HIV.
R5 CXCR4 using strains p
Caracteristics 60 (83.3%) 12 (16.7%)
Gender Male 58 (96.7%) 10 (83.3%) 0.13
Exposure MSM* 53 (88.3%) 9 (75.0%) 0.35
Age (mean) 32.65 (61.06) 33.08 (63.30) 0.88
Basal Viral Load
(log mean)
4.277 (60.11) 4.404 (60.28) 0.65
Basal CD4 count
(mean)
566.0 (627.50) 611.7 (6184.70) 0.65
Tip of V3 loop B 40 6 0.44
B0 20 6
Subtype B 56 12 0.47
non-B 4 0
CCR5 D32 4 (6,7%) 1 (8,3%)
GBV-C 17 (28,3%) 2 (16,7%)
HLA Allele B 27 5 (8,3%) 0
57 4 (6,7%) 2 (16,7%)
58 4 (6,7%) 2 (16,7%)
NRTI and PI
Primary Resistance
5 1 0.74
*Men who have sex with men.
At the tip of V3 loop, strains were classified as B if they harbor a proline or B0 if
they harbor a tryptophan or a related amino acid.
doi:10.1371/journal.pone.0030292.t001
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(GPG motif), whereas 18 harbored a tryptophan (GWG, the so
called B0 lineage), and eight other samples presented different
amino acids, including phenylalanine (2), leucine, glycine,
methionine, threonine and valine (1 each). All these alternative
amino acids are encoded by nucleotide triplets that are closer to
the one encoding tryptophan (TGG) than the ones that encode
proline at this position in this specific group of patients (CCA/G/
T), thus suggesting that they are derived from the B0 lineage. The
A316T substitution was detected in 15 individuals, whereas the
I323V substitution was detected in only two subjects; both
mutations were selected for by maraviroc in vitro, which lead to a
plateau in the PhenoSense HIV Entry Assay (Monogram
Biosciences, CA), preventing maximal inhibition by maraviroc
[29] (Figure 1). Interestingly, 12 out of the 15 cases presenting
A316T substitution appeared among the 26 B0-related strains,
compared to three out of the 42 clade B strains (Fisher’s exact test
p = 0.0003).
Phylogenetic relationships using all of the samples revealed only
one pair of patients presenting evidence of clustering based on the
low bootstrap values (below 98%, as previously suggested) [30].
This indicates that the majority of individuals analyzed were
epidemiologically unrelated, and clear evidence of convergence
towards CXCR4 sequences was not detected (Figure 2).
Overall, the mean and median CD4+ T cell counts were 551.5
and 529 cells/mL, respectively at baseline, and 537.9 and 475
cells/mL, respectively at visit 6. These CD4+ T-cell counts
represented a mean and median declines of 213.6 and 254 cells
from baseline over this 78-week period (visit number 6).
Specifically, the mean CD4 decline was 25.6 cells/mL for R5-
infected individuals, compared to 2168.9 cells/mL among
individuals infected with CXCR4-utilizing strains. The Cox
proportional-hazards regression revealed a risk ratio for CD4+ T
cell count decline to a level below 350 cells/mL of 0.99 for higher
baseline CD4 T cell count (protective effect, p = 0.0001) and 5.1
for X4 strains (p = 0.007). When age was kept in the model, the
age risk ratio was 1.1 with a borderline p value of 0.058, but the
risk ratio for X4 viruses increased to 10.1 (p = 0.001) whereas the
risk ratio for high baseline CD4 remained at 0.99 (p = 0.007), thus
suggesting that age enhances the effect of X4 strains on CD4
decline over time.
The mean CD4+ T cell count at baseline among individuals
with baseline viral loads above 100,000 copies/mL (after visit 2)
was 434.7 cells/mL, compared to 572.5 cells/mL in individuals
with baseline viral loads below 100,000 copies/mL (Mann-
Whitney p = 0.046). At visit number 6, mean CD4+ T cell counts
were 489 versus 543.5 for patients with viral loads .100,000 and
,100,000, respectively (Mann-Whitney p = 0.56). Interestingly,
there was no statistically significant difference in CD4 T cell
decline between these two groups over this short period of time;
the CD4 T cell count evolution slope was +0.3460.55 for patients
with .100,000 copies/mL, compared to 20.4361.3 among
individuals with baseline viral loads ,100,000 copies/mL. We
hypothesize that the initial impact on the CD4 T cell count among
individuals with higher viral loads followed by partial recovery of
CD4+ T cells after reaching the set point may obscure the impact
of persistent higher viral loads (i.e.; .100,000 copies/mL) in the
CD4 T cell decay during short term follow-up.
Fifty-seven individuals who were followed for up to 78 weeks
and presented CD4+ T-cell counts above 350 cells/mL at baseline
were evaluated and included in the disease progression analysis
(Figure 3). Forty-seven individuals predicted to have CCR5 strains
and 10 individuals predicted to have CXCR4 strains presented
with baseline CD4.350 cells/mL; after 78 weeks, 33 patients with
R5 strains and 1 patient with CXCR4 strains had a CD4 count
.350 cells/mL (p = 0.001, Fisher’s exact test). As seen in Figure 4,
the slope of CD4 decline was minus 2.07 for individuals with
CXCR4-utilizing viruses, compared to minus 0.17 for R5-infected
individuals. The probability of CD4 decline from above to below
350 cells/mL over time was similar for individuals infected with
clade B and clade B0 viruses (Fisher’s exact test p = 0.5). There was
no association between CD4+ T-cell count decline to below 350
cells/mL over time and demographic characteristics, HIV-1
subtype, gender, or baseline viral loads.
Overall, five individuals presented the CCR5 D32 allele (6.9%),
19 presented GBVC viremea (26.4%), 5 presented HLA_B*27
(6.9%), 6 presented HLA_B*57 and 6 HLA_B*58, and none of
these variable were statistically correlated to the CD4 decline or
viral tropism.
Discussion
We have established a well-characterized cohort of recently
infected individuals, and therefore, we were able for the first time
to describe the natural progression of HIV disease in Brazil based
on CD4+ T cell decline over time vis a vis the genetic
characterization of the infecting viruses. Individuals coming from
five counseling and testing sites in the city of Sa˜o Paulo were
recruited from 2002 to 2007 after being detected as having recent
HIV infection according to the STAHRS definition. To maximize
the odds of true recent HIV infection based on the laboratory
results, we confirmed that recruited individuals were able to fully
seroconvert in the follow-up visits, thus becoming seropositive for
the less sensitive STAHRS assay. Using this strategy, we analyzed
72 individuals in which the HIV-1 V3 region of gp120 was
characterized from samples obtained during the second visit,
approximately nine to 12 weeks after recruitment. We also have
been able to demonstrate that CXCR4-utilizing viruses were
predicted to be present in 12 out of 72 individuals (17%) at that
time, which is in accordance with the range described in the
literature (4% to 15.9%) [31,32,33].
It has been consistently reported that individuals are initially
infected with CCR5-utilizing strains. It has been recognized using
mathematical models that 75% of individuals will be infected by
only one HIV-1 strain whereas the remaining 25% will be infected
by two to five HIV strains [34]. This genetic restriction occurs in
spite of the transmission route, and it is so significant that only one
variant may be selected from several quasispecies from different
blood donors after the transfusion of platelets coming from
different HIV-infected individuals [35]. Therefore, we believe that
the V3 sequence profiles characterized in our study are an
accurate representation of the homogeneous quasispecies present
at that stage of HIV infection. It is also known that the change in
HIV-1 tropism from R5 to X4 receptors generally occurs late in
the disease when viruses start to preferentially replicate in the
thymus rather than in the gastrointestinal tract, and the detection
Figure 1. Amino acid alignment of V3 sequences. Subtype B sequences were aligned with the consensus sequence. Amino acid positions
appear at the top of each alignment, with dots indicating identities whereas dashes indicate deletions. # indicates the N-linked glycosylation site,
* indicates the GPGR motif at the tip of the V3 loop, and 1 indicates positions 316 and 323 (HXB2 positions), which are associated with in vitro
selection of maraviroc resistance (316T and 323 V substitutions are shaded) [29]. Inferred tropism is indicated to the right of each sequence (CXCR4-
using strains are named X4 for the sake of simplicity).
doi:10.1371/journal.pone.0030292.g001
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of X4 strains is correlated with rapid disease progression.
(reviewed in reference [33]) Detection of CXCR4-tropic strains
early in the course of disease may be attributed to faster evolution
from initial R5 to X4 viruses or transmission of dual-tropic viruses,
and we believe that these two possibilities may justify the high
proportion of CXCR4-tropic viruses found in our cohort.
Not surprisingly, we were able to observe the association
between the presence of CXCR4-utilizing strains and faster
disease progression as characterized by CD4+ T cell counts below
350 cells/mL. Although baseline CD4+ T cell count was not
statistically different between the two groups, the decrease to levels
below 359 cells/mL could somewhat be biased by the slightly lower
baseline levels in subjects with predicted CXCR4 using viruses
(566 versus 611 cells/mL). It is unclear whether the association of
faster disease progression with CXCR4-using strains represent a
cause or a consequence of HIV-1-related immune suppression.
However, the detection of CXCR4-using strains during recent
infection in a group of patients with relatively higher CD4+ T cell
levels and the observation of the steepest CD4+ T cell decline
among these individuals may indicate that this phenomenon is
more likely to be the cause rather than a consequence of immune
suppression. Therefore, our findings stress the possibility of the
presence of strains with more alleged in vitro pathogenicity during
the early phases of HIV infection, and also suggest that, even
Figure 2. Phylogenetic relationships between analyzed samples. D85_40 at the top is the North-American/European B consensus sequence.
* indicates CXCR4-using strains. Bootstrap values above 85% are indicated at the intersections of branches.
doi:10.1371/journal.pone.0030292.g002
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among recently infected individuals, rapid progression may be a
consequence of the early emergence of either X4 or dual-tropic
HIV strains.
We have not been able to correlate the pace of disease
progression and the presence of the Brazil-specific HIV-1 B strains
harboring a tryptophan residue at position 16 at the tip of the V3
loop (the so-called B0 strains), as had been previously suggested
[24,25]. It is interesting to note that B0 strains emerged very early
in the Brazilian epidemics, accounting for approximately 50% of
subtype B strains in Brazil [ref] [23]. It is also interesting that the
prevalence of B0 strains is lower among patients in lower CD4+ T
cell count strata, whereas the prevalence of the classical GPGR
strains remains unchanged and the prevalence of strains
presenting other amino acids at the tryptophan position inceases
(V3 position 16). Sera sample from patients harboring most of
these strains harboring other amino acids at position 16 will react
with specific B0 peptides and not with GPGR peptides, thus
suggesting that they have evolved from B0 strains [23]. As
tryptophan is coded by the TGG nucleotide triplet, it is
conceivable that the common hypermutation process observed
in HIV (G to A substitution) may lead to a disappearance of
tryptophan over time because TGA, TAG and TAA are stop
codons; therefore, tryptophan may be replaced by other related
amino acids. One possible explanation for the sustained
prevalence of B0 strains in the Brazilian population may be
related to the fact that most HIV transmission occurs during the
first years of infection, a time when B0 strains are still present in an
infected individual. We therefore think that the lack of correlation
between slower disease progression and B0 strains found in our
study is accurate because by the time the disease progresses in B0-
infected individuals, the tryptophan residue may have already
been replaced by other amino acids. One interesting finding was
the high prevalence of A316T substitution at the V3 region
(HXB2 position) in this set of samples. As previously mentioned,
these mutations have been selected by maraviroc in cell culture,
leading to decreased susceptibility to this drug [29]. The impact of
these mutations has been confirmed by reverse mutation, which
Figure 3. Associations between inferred tropism and time to CD4 decline to levels below 350 cells/mL (survival probability). There
was a statistically significant association between the presence of CXCR4-using viruses (X4) in the genotype at baseline and an earlier time to CD4
decline below 350 cells/mL (log rank P = 0.0450). The mean time to CD4 decline below 350 was 51.3163.66 and 34.14610.61 months for R5- and X4-
infected individuals, respectively.
doi:10.1371/journal.pone.0030292.g003
Figure 4. CD4 decline over time in individuals infected with R5
or CXCR4-using viruses (mean initial CD4+ T cell counts of
558.5 and 481.4 respectively).
doi:10.1371/journal.pone.0030292.g004
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restored wildtype susceptibility to maraviroc. However, this
mutation has been reported to be exceedingly rare in clade B
viruses, accounting for only two out of 23,000 sequences in the Los
Alamos HIV sequence database [29]. Another interesting finding
was the association of A316T substitution with the Brazilian clade
B strains (B0), which are extremely common in Brazil and rare
elsewhere. Therefore, the phenotypic impact of this substitution on
maraviroc susceptibility in B0 strains deserves further confirma-
tion.
We also investigated the influence of other co-factors related to
HIV-1 disease progression such as the CCR5 polymorphism,
GBVC viremea, and presence of ‘‘protective’’ HLA profiles such
as HLA B*27, B*57 and/or B*58 and were not able to find any
statistic correlation with CD4+ T cell decline, perhaps due to the
small number of patients here analyzed.
We recognize that this study may lack sensitivity and/or
specificity in detecting patients infected by X4 or dual-tropic/
mixed HIV populations because phenotypic assays were not used
in this study. However, we achieve the objective of predicting
genotypic correlates of HIV-1 disease progression using available
tools. Our findings confirm the similar results of another recent
study [36], and we believe that our findings demonstrate the
necessity of trying to predict HIV-1 co-receptor use among
recently infected/diagnosed naı¨ve individuals because it may
predict which individuals will be more likely to progress faster in
their HIV-related immune deficiency, and it may perhaps suggest
that a safer approach in dealing with these individuals could be an
earlier initiation of antiretroviral therapy. For the purpose of this
sort of HIV-1 characterization, genotype-based techniques may
prove to be more cost-effective than phenotypic assays because
they are less cumbersome, easily available, and less expensive.
Methods
Ethics Statement
Informed written consent was obtained from all the patients and
the study was approved by the Ethics Committees and the
Institutional Review Board of the Federal University of Sao Paulo
[#0919/01].
Cohort characterization
A cohort of individuals recently infected with HIV was initiated
in May 2002. Individuals seeking free and anonymous testing and
counseling services offered by the City of Sa˜o Paulo Health
Department and identified as infected with HIV-1 were offered to
undergo the Serologic Testing Algorithm for Recent HIV
Seroconversion (STARHS) after signing an initial IRB-approved
informed consent. They were invited to join the cohort if recent
HIV infection was detected (see below). As of May 2002, we were
able to recruit 72 individuals in which env V3 characterization was
possible. Recruited individuals were followed every three to four
months after the initial clinical visit [37].
Characterization of recent HIV-1 infection using the
Serologic Testing Algorithm for Recent HIV
Seroconversion (STARHS)
The VironostikaH HIV-1 Micro-ELISA System (bioMe´rieux
Inc., Durham, NC, USA) was used to retest the original HIV-
positive samples. The Vironostika LS/EIA tests a 1:20,000
dilution of the specimen under modified incubation conditions.
Specimens found to be positive on the S/EIA and negative on the
LS/EIA are considered to represent recent infection [38,39]. This
method is based upon the slow rate of increase in antibody titers
observed during the early period of infection, as well as on data
from study subjects with known dates of seroconversion. Based
on the calibration of the assays and on a defined threshold, the
serologic testing algorithm for recent HIV seroconversion
(STARHS) classifies HIV infection as recent or long-standing
depending on the differential HIV antibody titer. The assay
performs uniformly on HIV-1 subtype B, and the mean window
period between seroconversion on the S/EIA and seroconver-
sion on the LS/EIA is 170 days, with a 95% confidence interval
(95% CI) of 145–200; we therefore estimated incidence based on
the 170-day period. The STARHS was repeated in samples
collected six months after the initial visit to document full
seroconversion and to confirm the true positive nature of recent
HIV infections the enrolled individuals, since 2% of the cases
can be falsely classified to be seroconverters. Additionally, false
recency rate (FRR) is population specific occurring among AIDS
cases, elite controllers, and HAART suppressed patients in the
population under study, which were not the case the studied
population [40,41]. All testing was performed at the Retrovi-
rology Laboratory of the Federal University of Sa˜o Paulo,
located in Sa˜o Paulo, Brazil. Volunteers were also seen by an
Infectious Diseases physician to determine whether the clinical
and laboratory evaluation was compatible with a recent
infection.
HIV extraction, amplification, and sequencing
We selected proviral DNA rather than RNA given that, for
HIV-1 tropism evaluation, proviral DNA may constitute a more
sensitive method to detect CXCR4-utilizing strains [26]. Further-
more, as the patients in this study were evaluated at a time point
close to primary infection, the divergence between these two
compartments would not have been significant. Samples analyzed
were from the second visit, which occurred approximately 9 to 12
weeks after enrollment in the cohort. Proviral HIV-1 DNA was
purified using the QIAamp blood kit (Qiagen, Santa Clarita, CA,
USA), in accordance with the manufacturer’s instructions. To
analyze the V3 region of gp120 I, a 1.2-kb fragment of V1–V5 was
amplified in the first round and a 350-bp fragment of C2V3C3
was amplified in the second PCR, as previously described [42].
The protease and reverse transcriptase regions of the pol gene were
also amplified to assess primary HIV-1 resistance to antiretrovirals,
as previously described [43]. Purified PCR products were
sequenced bi-directionally with an ABI PRISM BigDye Termi-
nator Cycle Sequencing Ready Reaction Kit and Ampli Taq DNA
Polymerase (Applied Biosystems, Foster City, CA, USA). Se-
quences were corrected and assembled using the Sequencher 4.0
program (Genecodes, Ann Arbor, MI, USA).
Sequencing analysis and prediction of co-receptor use
The computer-modeled amino acid sequences were aligned and
used as a guide for manual editing of nucleotide sequence
alignments. The alignments were generated using the CLUSTAL
X program, version 3.0 [44]. For each alignment, phylogenetic
analyses were performed using the PHYLIP program package,
version 3.57. The DNAdist program was used to calculate distance
matrices based on the maximum-likelihood model, and neighbor-
joining trees were generated using the Neighbor and Consense
programs. Statistical significance was assessed with bootstrap tests
in a total of 100 replications. (GenBank accession numbers
pending). Co-receptor use was predicted using the bioinformatics
tool Geno2pheno[coreceptor] (false positive rate of 5, 10, and 20%
- Table S1), coreceptor.bioinf.mpi-inf.mpg.de [27]. We chose to
pursue the analysis using false positive rate of 10% which best
correlated with disease progression in this group of patients.
Disease Progression and HIV Recently Infection
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30292
Antiretroviral resistance analysis
Mutations related to resistance to NRTI, NNRTI, and PI
antiretrovirals were evaluated according to published guidelines,
which excluded common polymorphisms [45]. The prevalence of
mutations A316T and I323V in the V3 loop of gp120 (HXB2
positions), which display selection by treatment with maraviroc in
vitro and are related to decreased susceptibility to this inhibitor in
R5 strains, was also evaluated [29].
Detection and quantification of GB virus type C RNA
Viral RNA was extracted and reverse transcribed and a
fragment of the nonstructural 5a region (NS5a) was PCR amplified
as previously [46,47,48] described. After amplification, 5 ml of the
PCR product was used for electrophoresis analysis on a 2%
agarose gel. The positive and negative samples were corroborated
with nested RT_PCR that amplified a fragment of 344 bp of the
50 noncoding region (50 NCR) as previously described. After
amplification, 5 ml of the PCR product was used for electropho-
resis analysis on a 2% agarose gel.
CCR5 polymorphism
We obtained genomic DNA samples extracted from 300 ml of
buffy coat using a QIAamp Blood Kit (QIAGEN Inc, CA), using
the methodology indicated by the manufacturer. The presence of
CCR5D32, representing the heterozygous status of the allele by
the host was determined by polymerase chain reaction (PCR) as
previously described [49]. Subsequently, amplified products were
separated with electrophoresis in a 3% agarose gel for 40 minutes
at 110 mV and visualized with ethidium bromide under ultraviolet
light. The expected PCR product size was 241 bp for the wild-
type and 209 bp for the CCR5D32 alleles.
HLA class I genotyping
For each subject a blood sample was taken and genomic DNA
was extracted using a QIAamp DNA blood minikit (Qiagen). All
samples were analyzed for HLA-A, B and C alleles by reverse
polymerase chain reaction (PCR) sequence-specific oligonucleotide
(SSO) reverse hybridization on microbead arrays (Luminex TM
technology; Luminex Corporation, Austin, TX) after locus-specific
amplification on genomic DNA samples, using LABTypeH SSO
reagents (One Lambda, INC. Canoga Park, CA, USA). This assay
provided results at an intermediate level (groups of alleles), with
assignment of the four-digit allele in some cases.
Characterization of disease progression and statistical
analysis
All included individuals were followed at the HIV outpatient
clinics of the Federal University of Sa˜o Paulo. Clinical data, RNA-
HIV-1 viral loads and CD4+ T cell counts were collected every
three to four months. Disease progression was characterized by the
decrease of CD4+ T cell counts from above 350 cells/mL to levels
consistently below 350 cells/mL, and/or the initiation of
antiretroviral treatment. Antiretroviral treatment was initiated
according to the Brazilian Guidelines for HIV-1 Therapy (www.
aids.gov.br), which until 2009, recommended treatment for
patients with CD4+ T cell counts below 350 cells/mL or in the
presence of AIDS-defining conditions. The level of CD4 bellow
350 cells/mL was arbitrarily chosen since all individuals that
reached these levels started with antiretroviral treatment, thus
obscuring the disease progression end-point. On the other hand, in
this specific group of patients, antiretroviral treatment was not
initiated in any individual with CD4+ T-cell levels above 350
cells/mL. Statistical analyses were performed using the Chi-square
and Fisher’s exact test. The influence of the HIV-1 V3 sequence
on clinical outcomes was assessed by Kaplan–Meier analyses. Cox
proportional hazard regression was used to calculate univariate
and multivariate risk ratios (RR) and 95% confidence intervals
(CI). Baseline variables examined included HIV-1 baseline viral
load, CD4+ T cell count, age, HIV-1 subtype, gender, and route
of HIV-1 transmission.
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